Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes

Type 2 diabetes is associated with multimorbidity, microvascular and
macrovascular complications, and increased mortality (1). A holistic approach to
treatment with multifactorial risk-reduction strategies is recommended to improve long-
term diabetes outcomes (2). This post hoc analysis of the PIONEER 1–8 (excluding
PIONEER 6) trials evaluated the efficacy of oral semaglutide versus placebo or active
comparators in reducing four cardiometabolic risk factors. [Opening paragraph]